Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14762052 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MAPK1L3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL16620755 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MAPK1L3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL21814470 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MAPK1L3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL25933078 | 0.98 | ALDH1A1 (0.54) | ALDH1A1MAPK1L3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL29467614 | 0.96 | ALDH1A1 (0.49) | ALDH1A1MAPK1L3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL24983131 | 0.89 | ALDH1A1 (0.51) | ALDH1A1MAPK1L3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL30426434 | 0.88 | TDP1 (0.51) | ALDH1A1MAPK1L3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL31235810 | 0.88 | SMN1; SMN2 (0.56) | ALDH1A1MAPK1L3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL20107370 | 0.88 | ALDH1A1 (0.53) | ALDH1A1MAPK1L3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL21713242 | 0.87 | ALDH1A1 (0.56) | ALDH1A1MAPK1L3MBTL1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260061065-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2026-03-05 | — | — | US | disclosed |
| US-20250387504-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2025-12-25 | — | — | US | disclosed |
| WO-2025111431-A1 | ANTI-CD7 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | LES LABORATOIRES SERVIER (FR) | 2025-05-30 | — | — | WO | disclosed |
| EP-4525928-A1 | ANTIBODY DRUG CONJUGATES | Novartis AG (CH) | 2025-03-26 | — | — | EP | disclosed |
| EP-4525927-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | Novartis AG (CH) | 2025-03-26 | — | — | EP | disclosed |
| WO-2023223097-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225359-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225359-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| US-20230010108-A1 | A CONJUGATION LINKER CONTAINING 2,3-DIAMINOSUCCINYL GROUP | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-01-12 | — | — | US | disclosed |
| US-20220023438-A1 | SULFOMALEIMIDE-BASED LINKERS AND CORRESPONDING CONJUGATES | PIERRE FABRE MEDICAMENT (FR) | 2022-01-27 | — | — | US | disclosed |
| WO-2020065408-A1 | SULFOMALEIMIDE-BASED LINKERS AND CORRESPONDING CONJUGATES | PIERRE FABRE MEDICAMENT (FR) | 2020-04-02 | — | — | WO | disclosed |
| US-9879041-B2 | Saccharide dendritic cluster compounds as inhibitors of BACE-1 | VICTORIA LINK LIMITED (NZ) | 2018-01-30 | — | — | US | disclosed |
| US-9828341-B2 | Dendritic core compounds | VICTORIA LINK LIMITED (NZ) | 2017-11-28 | — | — | US | disclosed |
| US-9828341-B2 | Dendritic core compounds | VICTORIA LINK LIMITED (NZ) | 2017-11-28 | — | — | US | disclosed |
| US-20170152279-A9 | Saccharide Dendritic Cluster Compounds as Inhibitors of Bace-1 | UNIVERSITY OF LIVERPOOL (GB) | 2017-06-01 | — | — | US | disclosed |
| US-20170152279-A9 | Saccharide Dendritic Cluster Compounds as Inhibitors of Bace-1 | UNIVERSITY OF LIVERPOOL (GB) | 2017-06-01 | — | — | US | disclosed |
| US-20150291522-A1 | DENDRITIC CORE COMPOUNDS | CALLAGHAN INNOVATION RESEARCH LIMITED (NZ) | 2015-10-15 | — | — | US | disclosed |
| US-20150291644-A1 | Saccharide Dendritic Cluster Compounds as Inhibitors of Bace-1 | VICTORIA LINK LTD (NZ) | 2015-10-15 | — | — | US | disclosed |
| US-20150291644-A1 | Saccharide Dendritic Cluster Compounds as Inhibitors of Bace-1 | VICTORIA LINK LTD (NZ) | 2015-10-15 | — | — | US | disclosed |
| US-20150291522-A1 | DENDRITIC CORE COMPOUNDS | CALLAGHAN INNOVATION RESEARCH LIMITED (NZ) | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220023438-A1 | SULFOMALEIMIDE-BASED LINKERS AND CORRESPONDING CONJUGATES | CSGALNACT1, CD44, IGLV6-57 | ALDH1A1 1115/4885MAPK1 2905/4885L3MBTL1 4254/4885 |
| US-20150291522-A1 | DENDRITIC CORE COMPOUNDS | FLOT1, DBN1, DCTN3 | ALDH1A1 3695/4885MAPK1 4424/4885L3MBTL1 4842/4885 |
| US-20150291644-A1 | Saccharide Dendritic Cluster Compounds as Inhibitors of Bace-1 | BACE1, BACE2, APP | ALDH1A1 2404/4885MAPK1 2451/4885L3MBTL1 3839/4885 |
| US-20250387504-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | BID, BCL2, MCL1 | ALDH1A1 4315/4885MAPK1 3051/4885L3MBTL1 1429/4885 |
| US-20230010108-A1 | A CONJUGATION LINKER CONTAINING 2,3-DIAMINOSUCCINYL GROUP | DAO, DDO, DCLRE1A | ALDH1A1 60/4885MAPK1 4194/4885L3MBTL1 1197/4885 |
| US-20260061065-A1 | ANTIBODY DRUG CONJUGATES | FCGR2A, FCGR3B, BCL3 | ALDH1A1 3069/4885MAPK1 2112/4885L3MBTL1 264/4885 |
| US-20170152279-A9 | Saccharide Dendritic Cluster Compounds as Inhibitors of Bace-1 | BACE1, BACE2, APP | ALDH1A1 2404/4885MAPK1 2451/4885L3MBTL1 3839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.